<?xml version='1.0' encoding='utf-8'?>
<document id="19404318"><sentence text="Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia."><entity charOffset="71-79" id="DDI-PubMed.19404318.s1.e0" text="imatinib" /></sentence><sentence text="Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival"><entity charOffset="0-8" id="DDI-PubMed.19404318.s2.e0" text="Imatinib" /></sentence><sentence text=" However, plasma exposure to the drug from a given dosing regimen can vary widely among patients" /><sentence text=" Reasons for this may include incomplete adherence, intrinsic variations in the metabolism of imatinib, and drug-drug interactions"><entity charOffset="94-102" id="DDI-PubMed.19404318.s4.e0" text="imatinib" /></sentence><sentence text=" Data from two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response, leading to suggestions that maintaining imatinib blood concentrations above approximately 1000 ng/ml might be associated with improved outcomes"><entity charOffset="63-71" id="DDI-PubMed.19404318.s5.e0" text="imatinib" /><entity charOffset="163-171" id="DDI-PubMed.19404318.s5.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.19404318.s5.e0" e2="DDI-PubMed.19404318.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19404318.s5.e0" e2="DDI-PubMed.19404318.s5.e1" /></sentence><sentence text=" In patients who do not respond as well as expected to initial imatinib treatment, measurement of trough plasma concentration could assist with decisions about whether to increase the dose"><entity charOffset="63-71" id="DDI-PubMed.19404318.s6.e0" text="imatinib" /></sentence><sentence text=" Blood-level testing may also be helpful in other clinical scenarios: for example, when poor adherence is suspected, adverse reactions are unusually severe, or there is a possible drug-drug interaction" /><sentence text=" Further work is required to confirm prospectively the link between imatinib plasma concentrations and response, and to define effective trough concentrations in different patient populations"><entity charOffset="68-76" id="DDI-PubMed.19404318.s8.e0" text="imatinib" /></sentence><sentence text=" However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML"><entity charOffset="37-45" id="DDI-PubMed.19404318.s9.e0" text="imatinib" /></sentence><sentence text="" /></document>